DHS Working Papers No. 93
This is a detailed manual giving a step by step approach to undertaking the pharmacovigilance of antiretrovirals. It is intended to be a source of practical advice for Pharmacovigilance Centres and health professionals involved in HIV/AIDS prevention and treatment programmes. A number of WHO publica...tions are available that provide a background to pharmacovigilance and, as far as possible, that material will not be repeated here. Health officials, planners, the staff of Pharmacovigilance Centres, public health teams and all health workers should become familiar with these publications, which are: • Safety of Medicines: A guide to detecting and reporting adverse drug reactions
more
The Core Set of Indicators and respective Indicator Data Sheets aim to pave the way towards a common understanding, greater consistency and comparability across countries and alignment of results chains of German Development Cooperation in the field of health and social health protection with the in...ternationally recognized health systems framework of WHO and International Health Partnership (IHP+).
more
A toolkit for behavioural and social communication in outbreak response
BMC Infectious Diseases 2012, 12:352/1471-2334/12/352
Rev Esp Sanid Penit 2012; 14: 11-16 11
HIV/AIDS Programme
Policy Brief
Background paper prepared for the Education for All Global Monitoring Report 2012
Reports from Kenya, Sierra Leone, China and Sri Lanka
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Q4: Should community based rehabilitation be offered to children with intellectual disabilities?
Q8: What is the effectiveness, safety and role of pharmacological interventions, by non-specialized health care providers, for the broad category of Disruptive Behaviour Disorders (DBDs), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid (but not exclusively) Attention-Deficit ...Hyperactivity Disorder (ADHD)?
more
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?